Renalytix PLC (LSE: RENX) is a precision diagnostics company developing AI-driven kidney health tests. Its KidneyIntelX platform predicts disease progression in early-stage CKD patients, helping physicians tailor treatment. Despite regulatory and commercial challenges, Renalytix plays in a high-need space, and success could reshape how chronic kidney disease is managed.
差价合约 (CFD) 是一种复杂的金融工具，利用杠杆交易虽然可能放大收益，但同样也会加剧亏损风险，导致资金快速流失。数据显示，79.58% 的散户投资者在使用该提供商服务进行差价合约交易时出现账户亏损。在进行交易之前，请确保您充分了解差价合约的运作机制，并仔细评估自己是否有能力承担资金亏损的高风险。
评分与评论
评分与评论
